[ad_1]
A year after Autolus Therapeutics found itself a licensing partner in Moderna, Moderna is exercising its option to acquire the biotech’s proprietary compounds.
London-based Autolus disclosed the option Wednesday morning, with the mRNA giant exercising its option to license to an unspecified I/O target. The first agreement between the two companies was reached in August 2021, giving Moderna the option to use Autolus’ technology for up to four immuno-oncology targets.
Autolus has now received exercise fees and will continue to receive milestone payments and royalties. Shares of $AUTL initially rose 15 percent after the announcement.
Autolus CSO Martin Poole said in a statement that the collaboration with Moderna has been fruitful and that the collaboration is good going forward.
Atay has provided positive Phase I data for an opioid addiction candidate
Peter Thiel-backed startup Atay is reporting promising data for its OUD (Opioid Use Disorder) candidate.
The biotech reports that an oral formulation of drug candidate KUR-101, a deuterated key component of the kratom plant called mitragynin, has shown safety data and is well tolerated in patients. In the single ascending dose portion of the trial, no serious or serious adverse events were reported.
However, efficacy data are still lacking in the clinic compared to standard-of-care medications such as naltrexone and methadone. Those data are expected by the end of the year, which will compare a single dose of KUR-101 with a dose of oxycodone or placebo.
Chad Beyer, CEO of Atay Subsidiary Kures, which leads the KUR-101 program, said he was pleased with the results of the trial.
[ad_2]
Source link
